Development | Vaccine | Against Pneumonia
Against Pneumonia
A polyvalent protein vaccine targeting bacterial pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, and Klebsiella pneumoniae.

Pneumococcal infections are often challenging to treat due to widespread antibiotic resistance in circulating strains. Vaccination is the primary preventive measure. According to the WHO and the Russian Respiratory Society:
"Vaccination is the only way to prevent pneumococcal infection."

Universal Protection and Mechanism of Action
This innovation provides universal protection against pneumonia through both prevention and therapy. Key features include:

• Pathogen-derived proteins (not polysaccharides) as the core components.
• A recombinant protein combining immunogenic epitopes from conserved proteins of S. pneumoniae, H. influenzae, and K. pneumoniae, inducing a specific immune response with immunological memory.

Vaccine Composition
The candidate polyvalent vaccine consists of a highly purified recombinant protein containing:

• Immunogenic fragments of PspA (S. pneumoniae), OmpA (K. pneumoniae), and Protein E (H. influenzae).
• Flagellin domains (as an adjuvant).
• Rigid and flexible linkers between protein fragments to optimize spatial configuration for effective immunity.

АSafety is ensured by using recombinant protein as the active ingredient, produced via advanced molecular biology and biotechnological methods.